Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.64 |
| ▸ | AHR | P35869 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL401081 | 0.82 | LOXL2 (0.69) | LOXL2AHRHRH3HRH4AOC3 | |
| SCHEMBL28338445 | 0.82 | LOXL2 (0.69) | LOXL2AHRHRH3HRH4AOC3 | |
| SCHEMBL7169246 | 0.82 | LOXL2 (0.69) | LOXL2AHRHRH3HRH4AOC3 | |
| SCHEMBL31059889 | 0.82 | LOXL2 (0.69) | LOXL2AHRHRH3HRH4AOC3 | |
| SCHEMBL29403791 | 0.82 | LOXL2 (0.69) | LOXL2AHRHRH3HRH4AOC3 | |
| SCHEMBL28335219 | 0.80 | LOXL2 (0.67) | LOXL2AHRHRH3AOC3MTNR1A | |
| SCHEMBL108061 | 0.78 | LOXL2 (0.64) | LOXL2AHRHRH3HRH4AOC3 | |
| SCHEMBL219867 | 0.78 | LOXL2 (0.64) | LOXL2AHRHRH3HRH4AOC3 | |
| SCHEMBL3022232 | 0.78 | LOXL2 (0.64) | LOXL2AHRHRH3HRH4AOC3 | |
| SCHEMBL1854449 | 0.78 | LOXL2 (0.64) | LOXL2AHRHRH3HRH4AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10513531-B2 | Silylated derivatives of aromatic heterocycles | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-12-24 | — | — | US | disclosed |
| US-20180057514-A1 | SILYLATION OF AROMATIC HETEROCYCLES BY EARTH ABUNDANT TRANSITION-METAL-FREE CATALYSTS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057514-A1 | SILYLATION OF AROMATIC HETEROCYCLES BY EARTH ABUNDANT TRANSITION-METAL-FREE CATALYSTS | TEC, AURKA, TYR | LOXL2 2357/4885AHR 46/4885HRH3 77/4885 |
| US-10513531-B2 | Silylated derivatives of aromatic heterocycles | HNRNPH3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SBK3 | LOXL2 2710/4885AHR 239/4885HRH3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.